Universität zu Köln

Weber, Jan-Philipp and Wermke, Martin (2022). Small cell lung cancer-Established standards and new approaches. Innere Med., 63 (7). S. 724 - 731. Berlin: SPRINGER MEDIZIN. ISSN 2731-7099

Full text not available from this repository.

Abstract

Background Although the treatment and prognosis of many solid tumor types in the metastatic situation could be considerably improved during the last decade, for a long time no significant progress in the treatment of small cell lung cancer (SCLC) could be achieved. Objective The aim of this article is to describe the current treatment standard for SCLC and to discuss potential approaches for further improvement. Methods A selective literature search was carried out in PubMed and abstract lists of relevant conferences. Results Given the recent approval of two immunochemotherapy regimens based on the combination of anti-PD-L1 antibodies with platinum-etoposide, the therapeutic standard in the first line treatment of metastasized SCLC has finally been improved for the first time in three decades; however, the overall survival benefit has been modest with an improvement of just 2-3 months. In advanced lines of treatment no new approaches could so far show improved outcome compared with established chemotherapy protocols, such as topotecan and combinations of anthracycline, cyclophosphamide and vincristine. The slow progress in SCLC compared to non-SCLC, has been attributed to the complex biology, the exceptionally high proliferation rate and rapid development of resistance to chemotherapy. Increasing knowledge on the molecular and immunological principles of SCLC is increasingly opening up novel treatment approaches. Conclusion There has finally been a slow but clinically meaningful progress in the treatment of SCLC. Patients should be included in clinical trials at the latest after second line treatment, in order to accelerate the speed of the expansion of treatment options.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Weber, Jan-Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Wermke, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-663949
DOI:	10.1007/s00108-022-01362-4
Journal or Publication Title:	Innere Med.
Volume:	63
Number:	7
Page Range:	S. 724 - 731
Date:	2022
Publisher:	SPRINGER MEDIZIN
Place of Publication:	Berlin
ISSN:	2731-7099
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; RANDOMIZED-TRIAL; PLUS ETOPOSIDE; CISPLATIN; CYCLOPHOSPHAMIDE; VINCRISTINE; MULTICENTER Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66394